Dr. Delaloge is a medical oncologist and a researcher. She trained in France and Canada. She has been Head of the Breast Cancer Department at Gustave Roussy, Paris, France from 2004 until 2021. In 2021, she has been appointed director of the Cancer Interception Programme at Gustave Roussy.
Dr. Delaloge’s major areas of expertise and development are precision risk-based cancer prevention, real-life data, precision oncology and the organization of care in breast oncology. She has been investigator, principal investigator, national or international coordinator of more than 150 clinical trials over the last 25 years. She has been chair of the French National Breast Cancer Research Intergroup UCBG, until May 2019. She chairs the large H2020 EU-funded MyPeBS project and clinical trial, which aims at demonstrating the value of risk-based breast cancer screening among 85000 women randomized in 5 European countries, with the participation of 26 European and American partners.
Dr. Delaloge is the author of more than 275 international peer-reviewed publications and more than 500 presentations at international conferences (Scopus H-Index: 53). She is a board member of the European Society of Medical Oncology (ESMO) and of the French Society of Breast Care and Breast Pathology, and a member of the American Society of Clinical Oncology (ASCO) and participates to the elaboration of numerous national and international guidelines. She is breast cancer track chair for the ESMO-Asia conference 2021; prevention track chair for the MAP conference 2021; and will chair the ESMO Breast conference from 2022 to 2024.
Dr. Delaloge is breast specialty editor for European Journal of Cancer and genetics editor for The Breast, a member of the international advisory board of The Lancet Oncology. Dr. Delaloge is committed to numerous continuous teaching activities dedicated to doctors in training and medical students.